+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2014-01-08Number of Pages: 81

Nanomedicine Market (Application - Neurology, Cardiovascular, Anti-inflammatory, Anti-infective, and Oncology) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019

Nanomedicine Market: Snapshot

The rising applications of nanomedicine through breakthrough advancements in nanotechnology is perhaps the leading factor driving the global nanomedicine market. There has been a surge in research activities, by governments as well as private institutions, in the field of nanotechnology and in the experimental use of this technology to treat a variety of chronic conditions. This, coupled with high unmet medical needs, massive geriatric population, and growing incidence of chronic and acute diseases, is likely to give the market a significant boost.

Registering a double-digit CAGR during the course of the forecast period, the global nanomedicine market is slated to amount to a value of US$177 bn by 2019.

Growing Application of Nanomedicine Noted in Cardiovascular and Neurology Segments

The major application segments of nanomedicine include cardiovascular, neurology, anti-infective, anti-inflammatory, and oncology. Amounting to a value of US$65.5 bn by 2019, oncology stands to dominate the global nanomedicine market throughout the forecast period. Compared to conventional drug therapies, nanomedicine has proven to present a number of benefits when it comes to the treatment of tumors. Nanomedicine has enabled targeted drug delivery through enhanced permeation and retention (EPR), giving this treatment the advantage of specificity compared to conventional non-targeted drug therapies. As a result, there has been increased focus on research in the use of nanomedicine for the treatment of cancer.

In recent years, however, the focus on nanomedicine has moved toward its application in the neurology and cardiovascular segments. This can be attributed primarily to the rising availability of patient information and technological advancements. The cardiovascular segment is predicted to exhibit a CAGR of almost 16.0% during the forecast period.

Favorable Regulatory Scenario Lifts North America to Dominant Position in Nanomedicine Market

Accounting for an estimated share of over 35.0% in 2019, North America is slated to continue leading the global nanomedicine market throughout the forecast period. One of the most prominent factors that continues to drive this market is the increased presence of patented nanomedical products across the region. The presence of advanced and state-of-the-art healthcare infrastructure has greatly supported the development of nanomedical products such as nanorobots, DNA probes, monoclonal antibody-based immunoassays, nanosensors, and nanoparticle-based imaging agents.

A favorable regulatory environment is also a major factor boosting the nanomedicine market in North America. Conducive legal and regulatory environment allows for the development as well as early acceptance of nanotechnology-based medical products. In addition to this, the rising incidence of cardiovascular and neurological diseases, cancer, kidney disorders, and other chronic conditions has spurred the need demand for personalized medicine, thereby supporting the nanomedicine market in North America.

Although nanomedical products are still in their early stages of evolution and development in the emerging economies of Asia Pacific, the region is poised to expand at a rather strong pace over the course of the forecast period. Powered by countries such as India, China, and Indonesia, the APAC nanomedicine market is likely to be driven by increasing investments in R&D for the development and introduction of new drugs and therapies. A strong pipeline focused on various therapeutic areas is also anticipated to the growth of the nanomedicine Asia Pacific market.

Sigma-Tau Pharmaceuticals Inc., Celgene Corporation, Mallinckrodt plc, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., GE Healthcare, UCB SA, Nanosphere Inc., CombiMatrix Corp, and Abbott Laboratories are some of the prominent players in the global nanomedicine market. It has been observed that competition in this market is largely on the basis of particular segments and there are only a handful of participants that cater to the complete manufacturing process.

This report includes market estimations and forecast for nanomedicine products for the forecast period 2013 - 2019. The market size is represented in terms of USD billion and the market estimates and forecasts are calculated, considering 2012 as the base year. Moreover, market trends and recent developments have been kept into account while forecasting market growth and revenue for the period 2013 – 2019. The stakeholders for this report include present market players in the global nanomedicine market who aspire to increase their market share. Moreover, this report also targets the new players desiring to enter the global nanomedicine market. 
 
This report focuses on nanomedicine based products used for the purpose of various medical applications. Development of a nanomedicine takes years, incurring huge monetary investment. The product development process detailed in the market overview section of this report provides insights on the different events in the product development process with an approximate number of years consumed for that. According to this study, development of a new nenomedicine takes approximately nine to 25 years which are based on various technologies such as nanopores, liposomes, nanocrystals, virosome nanoparticles, nanorods, dendrimers, micelles, nanoemulsions, quantum dots, fullerenes and nanorobots.
 
The market dynamics section of this report analyzes the impact of drivers and restraints on the global nanomedicine market. The impact of these drivers and restraints on the global nanomedicine market provides a view on the market growth during the course of the forecast period. Increasing research activities to improve the drug efficacy coupled with increasing government support are considered to be some of the major driving factors in this report. Moreover, few significant opportunities for the existing and new market players are detailed in this report. 
 
Porter’s five forces analysis provides insights on the intensity of competition which can aid in decision making for investments in the global nanomedicine market. The market attractiveness section of this report provides a graphical representation for attractiveness of the nanomedicine market in four major regions – North America, Europe, Asia-Pacific and Rest of the World, based on the market size, growth rate and industrial environment in respective regions, in 2012.
 
The global nanomedicine market is segmented on the basis of application and geography and the market size for each of these segments, in terms of USD billion, is provided in this report for the period 2011 – 2019. Market forecast for this applications and geographies is provided for the period 2013 – 2019, considering 2012 as the base year.
 
Based on the type of applications, the global nanomedicine market is segmented into neurological, cardiovascular, oncology, anti-inflammatory, anti-infective and other applications. Other applications include dental, hematology, orthopedic, kidney diseases, ophthalmology, and other therapeutic and diagnostic applications of nanomedicines. Nanoparticle based medications are available globally, which are aimed at providing higher bioavilability and hence improving the efficacy of drug. There have been increasing research activities in the nanomedicine filed for neurology, cardiovascular and oncology applications to overcome the barriers in efficient drug delivery to the target site. Moreover, the global nanomedicine market is also estimated and analyzed on the basis of geographic regions such as North America, Europe, Asia-Pacific and Rest of the World. This section describes the nanomedicine support activities and products in respective regions, thus determining the market dynamics in these regions.
 
The report also provides a few recommendations for the exisitng as well as new players to increase their market share in the global nanomedicine market. Some of the key players of this market include GE Healthcare, Mallinckrodt plc, Nanosphere Inc., Pfizer Inc., Merck & Co Inc., Celgene Corporation, CombiMatrix Corporation, Abbott Laboratories and others. The role of these market players in the global nanomedicine market is analyzed by profiling them on the basis of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments.
 
The global nanomedicine market is categorized into the following segments:
  • Nanomedicine Market by Application
    • Neurology
    • Cardiovascular
    • Anti-Inflammatory
    • Anti-Infectives
    • Oncology
    • Others
  • Nanomedicine Market by Geography
    • North America
    • Europe
    • Asia-Pacific
    • Rest of the World (RoW)


 
 
Back To Top